Table 4 Comparison outcome of therapeutic dose group and sub-therapeutic dose group

Number

23

38

–

Female

9 (39.1)

22 (57.9)

0.155

Age

57.4 (17.3)

54.3 (13.7)

0.466

Acute DVT

15 (65.2)

24 (63.2)

0.871

Subacute DVT

8 (34.8)

14 (36.8)

 Median infusion rates 10,000 U/hour

2.5 (0.8–4.2)

2.5 (1.7–5)

0.891

 Median dose, 10,000 U

240 (60–1080)

240 (80–480)

0.456

 Median duration time, day

4 (2–12)

4 (2–14)

0.131

Balloon

3 (13.0)

3 (7.9)

1.000

Stent

1 (4.3)

6 (15.8)

0.236

 Undissolved

3 (13.0)

2 (5.3)

0.665

 Partial

15 (65.2)

28 (73.7)

 Complete

5 (21.7)

8 (21.1)

Clinical improvement

20 (87.0)

37 (97.4)

0.146

Decreased mid-thigh circumference, cm

2.1 (2.4)

2.4 (1.8)

0.716^a

Decreased mid-crus circumference, cm

2.2 (1.9)

3.1 (2.2)

0.268^b

 Major bleeding

0 (0)

0 (0)

1.000

 Minor bleeding

1 (4.3)

4 (10.5)

0.641